Compare Novo Nordisk A/S (NVO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Yum China Holdings Inc — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Yum China Holdings Inc trades at $42.55 (market cap $14.74B). The key difference: Novo Nordisk A/S is far larger — about 13.6× Yum China Holdings Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | YUMC | |
|---|---|---|
Market Cap | $200.69B | $14.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $57.95 |
52-Week Low | $35.29 | $40.18 |
Enterprise Value | $215.49B | $15.65B |
Dividend Yield | 3.98% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
YUMC trades at $43.34, down 0.6% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80 billion in 2025, and net income reached $929 million. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of the Pizza Hut Burger Bar to 300 locations.
The outlook remains positive given strong analyst support, with 14 buy ratings and a consensus pointing to 25.6% upside. Key risks include execution of expansion plans and macroeconomic pressures in China. The stock presents a value opportunity with a P/E of 15.88 and solid profitability metrics, but investors should monitor competitive dynamics and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
